This study aimed to determine if the baseline inflammatory profile of patients with HS could predict the response to treatment with Infliximab (IFX). High baseline levels of IL-6 and hs-CRP were predictive of nonresponse to IFX. Initial levels of hs-CRPand IL-6 are potential response markers for IFX treatment in HS. Here, IL6 is linked to histiocytic sarcoma.